IONCOCARE IONCOCARE
← Volver a noticias
Oncología enero 12, 2026 Por Dr. Adrián Pablo Huñis

Blood tests for early cancer detection (MCED): evidence, limitations and clinical reality

Biological basis, clinical evidence, regulatory positions and outlook for multi-cancer early detection (MCED) tests.

Blood tests that promise to detect several types of cancer before symptoms appear are gaining visibility. Dr Adrián Pablo Huñis reviews what they detect, what the evidence has shown, their risks and what use is reasonable today.

Dr. Adrián Pablo Huñis
School of Medicine, University of Buenos Aires Emeritus Member of ASCO Emeritus Member of ESMO Honorary Member of AMA

What MCED tests are

Multi-cancer early detection (MCED) tests analyse a blood sample for tumour signals, mainly fragments of circulating tumour DNA and methylation patterns. They are aimed at people without symptoms, and some also attempt to indicate the organ of origin.

Figure 3. Origin of cell-free and circulating tumour DNA, and its limitation in minimal disease.

Dr Adrián Pablo Huñis stresses a key point: a positive result is not a diagnosis, but the start of a work-up involving imaging and biopsy. And a negative result does not rule out cancer or replace recommended screening.

Table 1. Practical classification of MCED tests and their clinical attributes.

They should not be confused with liquid biopsy, which is used in patients with an established cancer diagnosis to guide treatment or follow-up. Moving into screening of healthy people completely changes the balance between benefits and risks.

Table 2. Critical differences between MCED tests and liquid biopsy in established cancer.

What the evidence shows

Published validations of methylation-based tests show very high specificity, above 99%, but moderate sensitivity: in the study by Liu and colleagues it was around 55% overall, and lower in early stages, precisely where detection would matter most.

Figure 2. Sensitivity by stage (illustrative): lower in stage I.

Prospective studies such as PATHFINDER show that the test can guide the diagnostic work-up, but they have not demonstrated a reduction in cancer mortality.

The predictive value problem

In the general population cancer is uncommon. As a result, even with very high specificity, a significant proportion of positive results will be false positives.

Figure 1. Relationship between cancer prevalence and positive predictive value (model with 55% sensitivity and 99% specificity).

This can lead to:

  • Cascades of unnecessary diagnostic tests.
  • Anxiety and incidental findings.
  • Overdiagnosis of lesions that would never have caused problems.
Figure 4. Clinical pathway after a positive MCED result and main risks.

What the agencies say

In the United States these tests are offered as laboratory-developed tests, but they are not FDA-approved for population screening, and the USPSTF does not recommend them for general screening. Societies such as ASCO and the American Cancer Society agree that studies with hard outcomes, such as mortality, are needed before widespread use.

A reasonable way forward

The author considers it sensible to explore their use in high-risk populations, as a complement to and never a substitute for validated screening, and always with clear protocols following a positive result.

Today, the most prudent use of MCED tests is in research or in tightly controlled programmes.

Bibliografía

  1. Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-59.
  2. Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77.
  3. Schrag D, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-60.
  4. Guerra CE, et al. Multicancer early detection tests at a crossroads. ASCO Educational Book. 2025. https://doi.org/10.1200/EDBK_473834
  5. American Cancer Society. Multi-cancer Early Detection (MCED) Tests. https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html
  6. U.S. Preventive Services Task Force. A and B Recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/

¿Te ha resultado útil esta noticia?

Comentarios

Sé el primero en comentar.

Deja tu comentario

Tu correo no se publicará. Los comentarios se moderan antes de aparecer.